# Pancreatic Cancer
Aspirin is unusually interesting in **pancreatic cancer**.
The strongest current evidence is still **preventive**, not post-diagnosis. Even so, the risk-reduction numbers are among the biggest in the aspirin literature, especially in people with **diabetes**. [Read the University of Southampton summary](https://www.uhs.nhs.uk/whats-new/news/researchers-find-regular-aspirin-cuts-pancreatic-cancer-risk-in-people-with-diabetes)
### Overview
Pancreatic ductal adenocarcinoma, or **PDAC**, sits at the overlap of **chronic inflammation**, **metabolic disease**, and **platelet activation**.
Aspirin intersects with all three. It suppresses **COX-driven prostaglandin signalling**, reduces platelet **TXA2**, and may blunt some of the inflammatory pressure that links diabetes and pancreatic carcinogenesis. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
This page matters most as a **prevention** page.
The post-diagnosis evidence is thin. But the prevention signal is strong enough to deserve its own place in the section.
### Key human data
#### Prevention and risk reduction
Several pancreatic studies report larger effect sizes than most other non-colorectal aspirin pages.
* **UK Biobank and University of Southampton, 2024:** Regular aspirin use was associated with about **20% lower pancreatic-cancer risk** in the general population and about **40% lower risk** in people with diabetes. [Read the study summary](https://www.uhs.nhs.uk/whats-new/news/researchers-find-regular-aspirin-cuts-pancreatic-cancer-risk-in-people-with-diabetes)
* **AACR case-control report, 2020:** Regular aspirin use was associated with a **46% lower risk** of pancreatic cancer after adjustment for smoking, BMI, and diabetes. Risk fell by about **8% for each additional year of use**. [Read the AACR summary](https://www.aacr.org/patients-caregivers/progress-against-cancer/aspirin-reduce-risk-pancreatic-cancer/)
* **Meta-analysis, 2020:** Pooling **13 studies** with about **28,440 participants**, aspirin use was associated with significantly lower pancreatic-cancer incidence, with a pooled **OR of 0.82**. [Read the meta-analysis](https://mednexus.org/doi/10.1097/JP9.0000000000000063)
* **Case-control data with duration signal:** Regular aspirin use was associated with **OR 0.52**, and each cumulative year of low-dose use reduced risk by about **6%**. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/)
* **Secondary analysis of cardiovascular trials:** Daily low-dose aspirin for **5 years or more** was associated with lower pancreatic-cancer mortality after follow-up, with a reported **HR of 0.43**. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/)
One observation stands out.
In the case-control study, aspirin discontinuation within **2 years** of pancreatic-cancer diagnosis was associated with sharply higher risk compared with continued use, with a reported **OR of 3.24**. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/)
That does not prove causation. But it argues against aspirin being a casual background variable.
#### Aspirin-specific effect
This may not be a generic NSAID story.
Several analyses suggest the protective signal is stronger for **aspirin** than for non-aspirin NSAIDs. That points toward platelet and **COX-1** biology, not just broad anti-inflammatory drug exposure. [Read the review](https://www.sciencedirect.com/science/article/pii/S1424390324007038)
#### Post-diagnosis data
This remains the weak area.
Pancreatic-cancer aspirin evidence is overwhelmingly **preventive**. Post-diagnosis and adjuvant data are still limited, partly because survival is often short enough to make large adjuvant trials difficult. [Read the Scientific Reports paper](https://www.nature.com/articles/srep15460)
### Mechanistic relevance
#### COX-2 overexpression
Pancreatic cancer has one of the clearer **COX-2** stories in solid tumours.
**COX-2** is markedly upregulated in PDAC tissue and largely absent from normal exocrine pancreatic tissue. That makes it a direct and unusually logical aspirin target. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
The pathway matters because:
* **COX-2** increases **PGE2**
* **PGE2** supports tumour-cell survival and proliferation
Aspirin interrupts this pathway at the prostaglandin level.
#### Platelet and tumour crosstalk
PDAC is also one of the most platelet-active cancers.
Pancreatic cancer has a very high burden of cancer-associated thrombosis, including classic **Trousseau's syndrome**. That is a clinical sign of intense platelet activation. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
This matters because platelets do more than clot.
In PDAC, platelet-derived signals can directly support tumour survival, metastatic spread, and chemotherapy resistance.
Key findings include:
* PDAC cells accelerate platelet aggregation
* platelet-derived **ADP** and **ATP** can support PDAC-cell survival
* **P2Y12** signalling is linked to **gemcitabine resistance**
* platelet extracellular vesicles can promote progression and metastasis
These findings make aspirin mechanistically relevant even where direct treatment data is still lacking. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
For the broader platelet mechanism, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md).
#### Diabetes as a modifier
This is one of the most important pancreatic subgroups.
Type 2 diabetes raises pancreatic-cancer risk through **insulin resistance**, **hyperinsulinaemia**, and **chronic systemic inflammation**. These changes also amplify **COX-2** and **PGE2** signalling.
That helps explain why aspirin's signal appears stronger in diabetic patients. In that setting, aspirin may be interrupting both the **metabolic driver** and the downstream inflammatory cascade at the same time. [Read the review](https://www.sciencedirect.com/science/article/pii/S1424390324007038)
#### Gemcitabine resistance
This is still an indirect aspirin story.
The best-defined resistance pathway in PDAC involves platelet-driven **P2Y12–AKT** signalling rather than aspirin directly. But aspirin still matters upstream because it reduces platelet activation overall. That gives it plausible relevance in resistance biology, even if that use remains unproven. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
### Clinical positioning
| Setting | Evidence | Position |
| ---------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------------------- |
| **Prevention in the general population** | Repeated observational signal, often in the **20% to 48%** range. [Read the University of Southampton summary](https://www.uhs.nhs.uk/whats-new/news/researchers-find-regular-aspirin-cuts-pancreatic-cancer-risk-in-people-with-diabetes) | One of the strongest aspirin prevention signals |
| **Prevention in people with diabetes** | About **40% lower risk** in a large recent analysis. [Read the University of Southampton summary](https://www.uhs.nhs.uk/whats-new/news/researchers-find-regular-aspirin-cuts-pancreatic-cancer-risk-in-people-with-diabetes) | Best-supported subgroup |
| **Long-duration low-dose use** | Duration-response signal plus lower pancreatic-cancer mortality after longer use. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/) | Long-term use looks most credible |
| **After aspirin discontinuation** | Higher risk reported after recent discontinuation. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/) | Consistency may matter |
| **Post-diagnosis or adjuvant use** | Very limited evidence. [Read the Scientific Reports paper](https://www.nature.com/articles/srep15460) | Investigational only |
| **Gemcitabine-resistance context** | Strong platelet rationale, but no direct aspirin trial. [Read the platelet-PDAC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/) | Mechanistically plausible only |
### Honest evidence assessment
Pancreatic cancer may have the biggest **risk-reduction numbers** in this section.
That does not mean it has the strongest overall clinical case.
The reason is simple. Most of the evidence is still **preventive**. There is very little direct evidence for people who already have PDAC. That matters because many readers in this section are looking for post-diagnosis relevance, not only prevention.
So the right framing is:
* the **prevention** signal is strong
* the **diabetes subgroup** is especially important
* the **platelet and COX-2 biology** is highly relevant
* the **adjuvant-treatment** case is still unproven
### Practical interpretation
This page is most actionable for people asking a **prevention** question.
The most useful clinical questions are:
1. Do I have **type 2 diabetes**, insulin resistance, or major metabolic-risk factors?
2. Is there a **family history** of pancreatic cancer?
3. Is aspirin already being considered for a **cardiovascular** reason that overlaps with this prevention question?
4. Given GI and bleeding risk, is **low-dose aspirin** reasonable to discuss with a GP or oncology team?
5. If I already have PDAC, is the relevant discussion about **platelet biology**, **clot risk**, or possible treatment interaction rather than proven adjuvant benefit?
That keeps the page clinically honest.
It also keeps the strongest message clear. Pancreatic cancer is one of the best aspirin **prevention** discussions in the whole section.
### References
* University of Southampton and UK Biobank 2024 — about **20%** lower pancreatic-cancer risk overall and **40%** lower risk in people with diabetes. [Read the study summary](https://www.uhs.nhs.uk/whats-new/news/researchers-find-regular-aspirin-cuts-pancreatic-cancer-risk-in-people-with-diabetes)
* AACR 2020 — **46%** lower pancreatic-cancer risk and about **8%** lower risk per year of use. [Read the AACR summary](https://www.aacr.org/patients-caregivers/progress-against-cancer/aspirin-reduce-risk-pancreatic-cancer/)
* 2020 meta-analysis — pooled **OR 0.82** across **13 studies**. [Read the meta-analysis](https://mednexus.org/doi/10.1097/JP9.0000000000000063)
* Case-control study with duration response, mortality signal, and discontinuation finding. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4091763/)
* 2024 review — aspirin-specific effect and diabetes modifier in pancreatic cancer. [Read the review](https://www.sciencedirect.com/science/article/pii/S1424390324007038)
* 2021 platelet-PDAC review — platelet crosstalk, **P2Y12**, and gemcitabine-resistance biology. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631477/)
* Yang et al., *Nature* 2025 — platelet **TXA2**, immune escape, and metastasis logic. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading)
* *Scientific Reports* 2015 — reduced pancreatic-cancer incidence with limited post-diagnosis data. [Read the paper](https://www.nature.com/articles/srep15460)
Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?
Feedback Form
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/pancreatic-cancer.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.